Hepatocellular carcinoma: Difference between revisions
| Line 19: | Line 19: | ||
==Management== | ==Management== | ||
*Supportive, symptomatic treatment | *Supportive, symptomatic treatment for complications and comorbidities | ||
**Cirrhotic jaundice | |||
**[[Hepatic encephalopathy]] | |||
**[[Anasarca]] | |||
**Variceal bleeding | |||
**Renal failure | |||
**Extrahepatic metastases, most commonly bone, lung, abdominal viscera | |||
**Paraneoplastic processes, such as hypoglycemia, hypocalcemia, polycythemia, feminization syndrome | |||
**Watery diarrhea, dehydration | |||
==Disposition== | ==Disposition== | ||
Revision as of 17:27, 13 October 2018
Background
- most common form of liver cancer
Clinical Features
- Risk factors include:
- Hepatitis B or C
- toxins (alcohol or aflatoxin)
- Metabolic conditions (hemochromatosis, alpha 1-antitrypsin deficiency, non-alcoholic fatty liver disease)
Differential Diagnosis
- Cirrhosis
- Hepatitis
- Budd-Chiari syndrome
Evaluation
- LFT, CBC, BMP, GGT
- Ultrasound
- Initial CT and MRI nonemergently
- Biopsy
- Surveillance with alfa-fetoprotein (AFP) in combination with US[1]
Management
- Supportive, symptomatic treatment for complications and comorbidities
- Cirrhotic jaundice
- Hepatic encephalopathy
- Variceal bleeding
- Renal failure
- Extrahepatic metastases, most commonly bone, lung, abdominal viscera
- Paraneoplastic processes, such as hypoglycemia, hypocalcemia, polycythemia, feminization syndrome
- Watery diarrhea, dehydration
Disposition
See Also
External Links
References
- ↑ Bialecki ES and Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005; 7(1): 26–34.